Floatz logo

Azacitidine

Acute Undifferentiated Leukemia

Therapeutic Advances in Childhood Leukemia ConsortiumSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

32 Active assets in the Acute Undifferentiated Leukemia cohort.

Asset / SponsorPhaseRating
Fludarabine
Fred Hutchinson Cancer Center
Phase 2BB
Cytosin-Arabinosid
Fred Hutchinson Cancer Center
Phase 3BB
DEXAMETHASONE
Therapeutic Advances in Childhood Leukemia Consortium
Phase 3BB
Cyclophosphamide
Masonic Cancer Center, University of Minnesota
Phase 3BB
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Azacitidine is also rated in:

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
73 / 100
View asset →
acute erythroid leukemiaDormant
BB
Indicative ·
71 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →